Gut microbiota-derived BA modifications (3-O-acylation and MCY conjugation) and microbial transformation products (e.g., TLCA) orchestrate glucose/lipid homeostasis by antagonizing intestinal FXR and activating TGR5, respectively, offering novel therapeutic avenues for metabolic disorders. This evidence concerns the gene GPBAR1 and metabolic disease.